Mediterr J Rheumatol 2019;30(1):33-7
Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions
Authors Information

Department of Rheumatology, University of Patras Medical School, Patras University Hospital, Patras, Greece

  1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003. [https://doi.org/10.1056/NEJMra0806188] [PMID: 19420368]
  2. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial 2. Arthritis Rheum 2000;43:2445-54. [https://doi.org/10.1002/1529-0131(200011)43:11%3C2445::AID-ANR11%3E3.0.CO;2-Q] [PMID: 11083267]
  3. Wells  AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford) 2009;48 Suppl 3:iii40-i4. [https://doi.org/10.1093/rheumatology/kep109] [PMID: 19487223]
  4. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheum 1996;35:364-72. [PMID: 8624641]
  5. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66. [https://doi.org/10.1056/NEJMoa055120] [PMID: 16790698]
  6. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease 1. Am J Respir Crit Care Med 2007;176:1026-34. [https://doi.org/10.1164/rccm.200702-326OC] [PMID: 17717203] [PMCID: PMC2078679]
  7. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology(Oxford) 2006;45:1005-8. [https://doi.org/10.1093/rheumatology/kei211] [PMID: 16490756]
  8. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708-19. [https://doi.org/10.1016/S2213-2600(16)30152-7] [PMID: 27469583] [PMCID: PMC5014629]
  9. Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009;68:1433-9. [https://doi.org/10.1136/ard.2008.096123] [PMID: 18782794]
  10. Daoussis D, Liossis S-NC. B cells tell scleroderma fibroblasts to produce collagen. Arthritis Res Ther 2013;15:125. [https://doi.org/10.1186/ar4392] [PMID: 24611177] [PMCID: PMC4061572]
  11. Tsuchiya N, Kuroki K, Fujimoto M, Murakami Y, Tedder TF, Tokunaga K et al. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 2004;50:4002-7. [https://doi.org/10.1002/art.20674] [PMID: 15593213]
  12. Komura K, Yanaba K, Horikawa M, Ogawa F, Fujimoto M, Tedder TF, et al. CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum 2008;58:3574-84. [https://doi.org/10.1002/art.23995] [PMID: 18975313]
  13. Hasegawa M, Fujimoto M, Takehara K, Sato S. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 2005;39:1-7. [https://doi.org/10.1016/j.jdermsci.2005.03.013] [PMID: 15885984]
  14. Lafyatis R, O’Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007;56:3167-8. [https://doi.org/10.1002/art.22847] [PMID: 17763433]
  15. Daoussis D, Liossis SNC, Tsamandas AC, et al. Experience with rituximab in scleroderma: Results from a 1-year, proof-of-principle study. Rheumatology 2010;49:271-80. [https://doi.org/10.1093/rheumatology/kep093] [PMID: 19447770] [PMCID: PMC2806066]
  16. Daoussis D, Liossis S-NC, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012;30:S17-22. [PMID: 22244622]
  17. Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 2017;45:625-31. Epub 2016 Oct 13. [https://doi.org/10.1016/j.semarthrit.2016.10.003] [PMID: 27839742]
  18. Jordan S, Distler JHW, Maurer B, Huscher D, van Laar JM, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2014;1-7. [https://doi.org/10.1136/annrheumdis-2013-204522] [PMID: 24442885]
  19. Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010;69:193-7. [https://doi.org/10.1136/ard.2008.095463] [PMID: 19103636]
  20. Bosello S, De Santis M, Lama G, Spanò C, Angelucci C, Tolusso B, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010;12:R54. [https://doi.org/10.1186/ar2965] [PMID: 20338043] [PMCID: PMC2888203]
  21. Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Rheum 2015;44:428-36. [https://doi.org/10.1016/j.semarthrit.2014.09.002] [PMID: 25300701]
  22. Smith V, Piette Y, Van Praet JT, Decuman S, Deschepper E, Elewaut D, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 2013;40:52-7. [https://doi.org/10.3899/jrheum.120778] [PMID: 23118116]
  23. Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016;387:2630-40. [https://doi.org/10.1016/S0140-6736(16)00232-4] [PMID: 27156934]
  24. Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, et al. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis 2018;77:1362-71. [https://doi.org/10.1136/annrheumdis-2018-213031] [PMID: 29853453] [PMCID: PMC6104680]
  25. Khanna D, Lin CJF, Kuwana M, Allanore Y, Batalov A, Butrimiene I, et al. Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3 Randomized Controlled  Trial [abstract]. Arthritis Rheumatol 2018; 70 (suppl 10). [https://acrabstracts.org/abstract/efficacy-and-safety-of-tocilizumab-for-the-treatment-of-systemic-sclerosis-results-from-a-phase-3-randomized-controlled-trial/]
  26. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 2018;378:35-47. [PMID: 29298160] [PMCID: PMC5846574]
  27. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. JAMA 2014;311:2490. [https://doi.org/10.1001/jama.2014.6368] [PMID: 25058083]
  28. Farge D, Burt RK, Oliveira MC, Mousseaux E, Rovira M, Marjanovic Z, et al. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplant 2017;52:1495-503. [https://doi.org/10.1038/bmt.2017.56] [PMID: 28530671] [PMCID: PMC5671927]
  29. Lafyatis R. Transforming growth factor β—at the centre of systemic sclerosis. Nat Rev Rheumatol 2014;10:706-19. [https://doi.org/10.1038/nrrheum.2014.137] [PMID: 25136781]
  30. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, et al. Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33. [https://doi.org/10.1002/art.22289] [PMID: 17195236]
  31. Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 2015;125:1-13. [https://doi.org/10.1172/JCI77958] [PMID: 26098215] [PMCID: PMC4563675]
  32. Spiera R, Hummers L, Chung L, Frech T, Domsic R, Hsuet V, et al. OP0006 Safety and efficacy of lenabasum (JBT-101) in diffuse cutaneous systemic sclerosis subjects treated for one year in an open-label extension of trial jbt101-ssc-001. Ann Rheum Dis 2018;77:52. [https://doi.org/10.1136/annrheumdis-2018-eular.3512]
  33. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med 2014;370:2071-82. [https://doi.org/10.1056/NEJMoa1402584] [PMID: 24836310]